Trial Profile
Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues - a Randomized, Double-blind, Placebo-controlled Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- Acronyms SKIP
- 20 Apr 2023 Results assessing the GLP-1 analogue dulaglutide as a new therapy for smoking cessation, published in the Trials.
- 07 Sep 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2021 Planned End Date changed from 31 Mar 2021 to 30 Sep 2022.